Cross-Sector entity

Cologuard

Product
5.7

Abbott Laboratories is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Across a 39-day span, the pace is roughly 0.5 stories per week. The busiest single day carried 2. The clearest coverage concentration is acquisition: 1 of 3 stories, with the rest divided among 2 other categories.

3 verified stories tracked

Last mentioned: 1d ago

RSS updates
Share

Entity pulse

Recent coverage · Cologuard

↑
3 stories
5.7 avg impact
67% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.

  • 67% positive
  • 33% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Cologuard

Abbott Laboratories is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Across a 39-day span, the pace is roughly 0.5 stories per week. The busiest single day carried 2. The clearest coverage concentration is acquisition: 1 of 3 stories, with the rest divided among 2 other categories. The tracked stories average 2 original sources each. We currently track 3 Cross-Sector stories that mention Cologuard, published between July 17, 2026 and August 24, 2026.

Stories tracked
3
Per week
0.5
Sources per story
2

Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Cologuard. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Cologuard 3

Healthcare market trends Neutral 5

Abbott's 42% Diagnostics Surge vs Thermo Fisher's Recovery: Which Wins?

For health system executives, clinical lab directors, and healthcare investors, this comparison is a real-world barometer of whether diversified diagnostic platforms or life sciences recovery will shape vendor and research spending. Abbott's 42% diagnostics jump to $3.09B, driven by Cologuard and Exact Sciences, points to durable non-invasive screening demand. Thermo Fisher's improving pharma and biotech activity signals a potential rebound in research tool budgets.

2 sources

Source: insidermonkey.com · finance.yahoo.com

Healthcare medical devices Positive 6

Abbott lifts 2026 EPS forecast to $5.45-$5.60 on 9% device growth

Abbott raises its 2026 profit outlook as medical device sales jump 9% to $5.85B and diabetes care climbs 11%, proving the resilience of advanced cardiac and CGM technologies. The beat and guidance hike signal that hospitals continue to prioritize high-acuity procedures even under volume pressure.

2 sources